Recombinant human bone morphogenic protein (rhBMP) 9 has recently been reported to have more osteopromotive potential in vitro when compared to rhBMP2. The aim of the present study was to investigate the bone-inducing potential of rhBMP2 and rhBMP9. We compared rhBMP2, rhBMP7, and rhBMP9 at five different concentrations and showed convincingly that rhBMP9 possesses much greater potential for osteoblast differentiation even at 20 times lower concentrations in vitro. We further show that Noggin, an inhibitor for rhBMP2-induced osteogenesis, did not alter rhBMP9-induced osteogenesis. Thereafter, we show for the first time that rhBMP9 loaded onto atelo-collagen membranes is osteoinductive and has greater potential to form ectopic bone formation when compared to rhBMP2 even at four times lower doses. Similarly new bone formation of rhBMP2 and 9 when loaded on deproteinized bovine bone mineral (DBBM) was investigated in a rabbit calvarial defect. At 8 weeks, both rhBMP2 and rhBMP9 induced significantly higher new bone formation when compared to DBBM alone samples. Interestingly, once again four times lower dose of rhBMP9 group induced comparable or even greater levels of new bone height and new bone area when compared to the rhBMP2 group. The present study revealed that (1) rhBMP9 is capable of inducing ectopic new bone formation in vivo and (2) up to four times lower doses of rhBMP9 may be utilized to regenerate same-size bone defects when compared to rhBMP2. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 1561-1574, 2018.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbm.a.36359DOI Listing

Publication Analysis

Top Keywords

compared rhbmp2
24
times lower
16
bone formation
16
rhbmp9
9
rhbmp2
9
bone
9
bone-inducing potential
8
rhbmp9 compared
8
rhbmp2 rhbmp9
8
greater potential
8

Similar Publications

Reducing Healing Period with DDM/rhBMP-2 Grafting for Early Loading in Dental Implant Surgery.

Tissue Eng Regen Med

January 2025

Department of Oral and Maxillofacial Surgery, Section of Dentistry, Seoul National University Bundang Hospital, 172 Dolma-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Republic of Korea.

Background: Traditionally, dental implants require a healing period of 4 to 9 months for osseointegration, with longer recovery times considered when bone grafting is needed. This retrospective study evaluates the clinical efficacy of demineralized dentin matrix (DDM) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) during dental implant placement to expedite the osseointegration period for early loading.

Methods: Thirty patients (17 male, 13 female; mean age 55.

View Article and Find Full Text PDF

This study aimed to investigate the impact of varying the formulation of a specific peptide hydrogel (PepGel) on the release kinetics of rhBMP-2 in vitro. Three PepGel formulations were assessed: (1) 50% / (peptides volume/total volume) PepGel, where synthetic peptides were mixed with crosslinking reagents and rhBMP-2 solution; (2) 67% / PepGel; (3) 80% / PepGel. Each sample was loaded with 12 µg of rhBMP-2 and incubated in PBS.

View Article and Find Full Text PDF

Objective: To 1) create a novel tissue-engineered bone graft comprising the osteoinductive oxysterol Oxy133 and 2) compare the osteogenic capability of this novel bone graft with bone graft substitutes previously examined.

Methods: Oxy133 was homogeneously incorporated into a biomimetic (BioMim) bone graft substitute comprising extracellular matrix and calcium phosphates. Two iterations of the graft were created: one corresponding to an implant-dose of 2.

View Article and Find Full Text PDF
Article Synopsis
  • The study explores new treatments for extensive bone loss, focusing on the potential of melatonin and growth factors in bone remodeling and repair.
  • Researchers evaluated how various concentrations of melatonin and rhBMP-2 influence the expression of bone-related cytokines and markers in rats with bone injuries.
  • Results indicate that higher concentrations of melatonin combined with rhBMP-2 showed some improvements in bone repair, suggesting a need for better application methods in future research.
View Article and Find Full Text PDF

Application of RhBMP-2 in Percutaneous Endoscopic Posterior Lumbar Interbody Fusion.

BMC Surg

November 2024

Department of Spinal Surgery, Ganzhou People's Hospital, No. 16 Meiguan Avenue, Zhanggong District, Ganzhou City, Jiangxi Province, 341000, China.

Article Synopsis
  • * A total of 102 patients with lumbar spondylosis were divided into two groups: one receiving RhBMP-2 and the other receiving autologous bone for spinal fusion, with their recovery and outcomes measured over 12 months.
  • * Results showed that the RhBMP-2 group had significantly better scores for spinal function, a higher fusion rate (86.27% vs 54.90%), and lower cage displacement (5.88% vs 21.57%)
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!